Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ESRRA | P11474 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.47 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11067807 | 0.79 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL6516221 | 0.78 | KMT2A (0.73) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL11656245 | 0.77 | KMT2A (0.69) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL13342798 | 0.77 | MTNR1A (0.56) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL11685290 | 0.77 | HTT (0.56) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL11301317 | 0.76 | MEN1 (0.71) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL1122188 | 0.75 | KMT2A (0.63) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL18826484 | 0.73 | KMT2A (0.66) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL31704006 | 0.73 | MTNR1B (0.71) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL14221332 | 0.73 | S1PR2 (0.69) | SMN1; SMN2ALDH1A1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779127-B2 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779127-B2 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-14 | — | — | US | disclosed |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-03-14 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268829-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1517905-B1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-1517905-B1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES AND PYRIMIDINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2292614-A1 | Substituted pyrimidines as aurora kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-1746093-B1 | Process for preparing substituted pyrimidines | VERTEX PHARMA (US) | 2011-02-16 | — | — | EP | disclosed |
| EP-2277876-A1 | Substituted pyrimidines for the treatment of cancer | Vertex Pharmaceuticals Incorporated (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1746093-A1 | Process for preparing substituted pyrimidines | Vertex Pharmaceuticals Incorporated (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1746093-A1 | Process for preparing substituted pyrimidines | Vertex Pharmaceuticals Incorporated (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060270660-A1 | inhibitors of FLT-3, Aurora-1, Aurora-2, and Aurora-3 protein kinases; leukemia; N-{4-[4-(5-Methyl-2H-pyrazol-3-ylmethyl)-6-(4-propyl-piperazin-1-yl)-pyrim- idin-2-ylsulfanyl]-phenyl}-propionamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270660-A1 | inhibitors of FLT-3, Aurora-1, Aurora-2, and Aurora-3 protein kinases; leukemia; N-{4-[4-(5-Methyl-2H-pyrazol-3-ylmethyl)-6-(4-propyl-piperazin-1-yl)-pyrim- idin-2-ylsulfanyl]-phenyl}-propionamide | FLT3, AURKA, AURKC | SMN1; SMN2 3796/4885ALDH1A1 2008/4885POLB 2600/4885 |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | SMN1; SMN2 2568/4885ALDH1A1 3688/4885POLB 387/4885 |
| US-20130066069-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | SMN1; SMN2 2568/4885ALDH1A1 3688/4885POLB 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.